Print Handheld Contrast

Leonard Luyt, PhD

Principal Investigator: London Regional Cancer Program, London Health Sciences Centre, London, Ontario
Assistant Professor: Department of Oncology, University of Western Ontario, London, Ontario
Cross Appointments: Department of Chemistry, Department of Diagnostic Radiology & Nuclear Medicine

University Website: http://publish.uwo.ca/~lluyt/

Mailing Address

London Regional Cancer Program
Room A4-817A
Cancer Research Laboratory Program
790 Commissioners Rd. E.
London, Ontario
Canada N6A 4L6

Tel: 519.685.8600, ext. 53302
Fax: 519.685.8646
Email: lluyt@uwo.ca

 

Staff and Trainees

Post-Doc

Tienabe Nsiama, Ph.D.

email: tienabe@gmail.com

phone: 519-685-8600 x56853

Graduate Students

Babak Behnam Azad, M.Sc.
email: bbehnam@ uwo.ca
phone: 519-685-8500 x56853

Brian Ngo

email: bngo@uwo.ca

phone: 519-685-8600 x53299

Dana Cruickshank

email: fouris17@hotmail.com

phone: 519-685-8600 x53299

Emily Simpson
email: esimpso8@uwo.ca
phone: 519-685-8500 x53299

Jen Hickey
email: jlhickey@ uwo.ca
phone: 519-685-8500 x53299

Kenn Esguerra
email: kenn.virgel@gmail.com
phone: 519-685-8500 x56853

Mark McFarland

email: mmcfarl7@uwo.ca
phone: 519-685-8500 x53299

Zhu Lin

email: zlin29@ uwo.ca
phone: 519-685-8500 x56853

 

 

Research Area

Bioorganic and medicinal chemistry, molecular imaging probe design, targeting cancer via GPCRs, radiochemistry.

Key Words:

molecular imaging, peptide receptors, G protein-coupled receptor, radiopharmaceuticals

Summary of Current Work

Our research program involves the design, preparation, and evaluation of new compounds for the imaging and treatment of cancer. Many cancer tumours have an abundance of peptide receptors located on the surface of the tumour cells, mostly belonging to the G protein-coupled receptor (GPCR) superfamily. By using the peptides that normally bind to these receptors as the starting point, we are designing variations of these compounds such that they will contain a radioactive component, yet still bind to the intended peptide receptor, and have appropriate in vivo behaviour. Thus, a radioactive peptide-like compound will be injected into a patient, will localize in the cancer tumour, and using an external camera an image of the tumour will be viewed. This approach also has potential use as a method of treatment for cancer.

As part of this program of creating new cancer imaging and therapeutic agents, new chemical methods and technologies for the preparation of these novel compounds are being developed. While radiopharmaceuticals are a primary focus of our research, our group is also pursuing probes for other molecular imaging modalities (such as optical imaging), and small molecule cancer therapeutics.Students involved in research in our group acquire synthetic organic chemistry, solid-phase organic chemistry, peptide/peptidomimetic design, bioconjugation, and radiolabelling skills. This research requires interaction with cancer and imaging scientists and group members are able to take projects from the basic chemistry stage through to animal model studies.

PubMed Publications

See my publications on PubMed